Posts

Showing posts from April, 2022

Remdesivir trial Results

 Drugs trial for coronavirus:- Antiviral drug Remdesivir helps patients hospitalised with Covid_19 recover faster and may also reduce mortality rate, according to the US National Institutes of Health( NIH) Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (P=0.059).

Acute Encephalitis Syndrome (AES)

Background :-  One among three long-standing mystery diseases listed in Wikipedia is acute encephalitis syndrome (AES) in Muzaffarpur, Bihar. This disease has remained for over two decades without determining a cause for it; hence it is called mystery disease. It occurs as annual seasonal outbreaks during the months of April – July, affecting hundreds of children with 40–60% mortality. Studies documented that cases coincided spatially and temporally with lychee cultivation. My investigation suggests that lychee consumption is the main cause of acute encephalitis syndrome. Objective:-  There are hundreds of children deaths due to acute encephalitis syndrome in Muzaffarpur due to lack hospital facilities, illiteracy, poor mental health and inadequate nutrient supply. Material and Methods:-  Study design In 2014, NCDC and US CDC investigated this syndrome, using hospital-based clinical surveillance, an epidemiological case-control study, and comprehensive and novel laborator...